%0 Journal Article
%T Clinical Evaluation of the Safety and Efficacy  of the Phytomedicine APIVIRINE Based on Aqueous Extracts of <i>Dichrostachys glomerata</i> (Forssk.). Chiov. (<i>D. cinerea</i>) in COVID-19 Patients without Signs of Severity
%A Daouda Ou¨¦draogo
%A Grissoum Tarnagda
%A Jean Claude Romaric Pingdwind¨¦ Ou¨¦draogo
%A Amed H¨¦ma
%A Simon Tiendreb¨¦ogo
%A Salfo Ou¨¦draogo
%A Geoffroy Gueswind¨¦ Ou¨¦draogo
%A Lazare Belemnaba
%A Noufou Ou¨¦draogo
%A F¨¦lix Dit Bondo Kini
%A Z¨¦kiba Tarnagda
%A Martial Ou¨¦draogo
%A Sylvin Ou¨¦draogo
%J International Journal of Clinical Medicine
%P 302-318
%@ 2158-2882
%D 2023
%I Scientific Research Publishing
%R 10.4236/ijcm.2023.146026
%X <strong>Background: </strong>Since the appearance of the COVID-19 pandemic, several drugs have also been proposed for the treatment of the COVID-19, but the therapeutic effectiveness of those drugs is not satisfactory. This situation has led to the search for therapeutic solutions based on recipes from traditional medicine. <strong>Aims:</strong> This study aimed to evaluate the clinical safety, efficacy and tolerability of the phytomedicine APIVIRINE in patients with non-severe COVID-19. <strong>Methods:</strong> Patients were included following defined criteria and followed on an outpatient basis until recovery in accordance with national guidelines for the management of single cases of COVID-19 in Burkina Faso. Vital signs, anthropometric parameters as well as electrocardiographic, hematological and biochemical examinations were measured on D4, D7, D14 and D21. Adverse events were recorded during maintenance. <strong>Results:</strong> The present study included 45 patients. The clinical signs present at inclusion were mostly cough (44.44%), asthenia (42.22%), headache (40%), and anosmia (35.55%). Dyspnoea and chest pain were less represented in 05 (11.11%) and 06 (13.33%) patients. Cough, dyspnoea, chest pain, fever, sore throat, headache, and nasal obstruction present at inclusion disappeared before Day 4 of treatment. Anosmia and asthenia disappeared before Day 7. At the inclusion visit (Day 1), CRP, WBC, and blood glucose were abnormal in 15 (33.33%), 13 (28.89%), and 11 (24.44%) patients respectively. In addition, 3 (6.66%) patients had elevated creatinine levels. Transaminases Alanine aminotransferase (ALAT) were elevated in 05 (11.11%) patients while Aspartate aminotransferase (ASAT) was elevated in 04 (8.89%) patients. After 4 days of treatment, the cure rate was 33.33% of patients and 48.89% after 7 days. The cumulative cure rate was 86.67% after 14 days of treatment. <strong>Conclusion: </strong>No serious side effects or allergic reactions were observed during treatment. No clinical complications were observed and all symptoms present resolved on the 7th day of treatment.
%K APIVIRINE
%K COVID-19
%K Clinical Study
%K Safety
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=125960